


SB-267268

Cat. No.:	HY-19306
CAS No.:	205678-26-8
Molecular Formula:	C ₂₂ H ₂₄ F ₃ N ₃ O ₄
Molecular Weight:	451.44
Target:	Integrin
Pathway:	Cytoskeleton
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	SB-267268 is a selective and nonpeptidic alpha(v)beta3 (αvβ3) and alpha(v)beta5 (αvβ5) integrins antagonist, with K _i s of 0.9, 0.5 and 0.7 nM for human αvβ3, monkey αvβ3 and human αvβ5, respectively. SB-267268 inhibits human and mouse αvβ3 with IC ₅₀ s of 0.68 and 0.29 nM, respectively. SB-267268 reduces angiogenesis and VEGF expression ^[1] .								
In Vitro	SB-267268 was much less potent for inhibition of human, mouse, and rat αvβ6 integrin. SB-267268 inhibits the attachment of both αvβ3-transfected HEK293 cells to microtiter plate wells precoated with arginine-glycine-aspartic acid (RGD)-containing matrix proteins with IC ₅₀ values of 12 nM. SB-267268 also inhibits vitronectin-mediated human and rat aortic smooth-muscle-cell (SMC) migration with IC ₅₀ values of approximately 12.3 nM and 3.6 nM, respectively ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	SB-267268 (60 mg/kg; bi-daily, i.p.) reduces blood vessel profiles (BVPs) in the inner retina by 50% ^[1] . In ROP mice treated with SB-267268, VEGF and VEGFR-2 gene expression in the inner nuclear layer (INL) and the ganglion cell layer (GCL) is reduced ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>Pregnant female C57BL/6 mice (ROP mice)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>60 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.p.; bi-daily</td> </tr> <tr> <td>Result:</td> <td>Reduced blood vessel profiles (BVPs) in the inner retina by 50%.</td> </tr> </table>	Animal Model:	Pregnant female C57BL/6 mice (ROP mice) ^[1]	Dosage:	60 mg/kg	Administration:	i.p.; bi-daily	Result:	Reduced blood vessel profiles (BVPs) in the inner retina by 50%.
Animal Model:	Pregnant female C57BL/6 mice (ROP mice) ^[1]								
Dosage:	60 mg/kg								
Administration:	i.p.; bi-daily								
Result:	Reduced blood vessel profiles (BVPs) in the inner retina by 50%.								

REFERENCES

[1]. Wilkinson-Berka JL, et al. SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1600-5.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA